Why the study?
Does intravenous administration of heparin, VK 744, ASA, or sulfinpyrazone reduce thrombus growth in a rat model of arterial thrombosis?
Does intravenous administration of heparin, VK 744, ASA, or sulfinpyrazone reduce thrombus growth in a rat model of arterial thrombosis?
In a rat model of arterial thrombosis, heparin was the most effective antithrombotic agent, while sulfinpyrazone was the most potent among the non-heparin agents tested.
Answers are grounded in this paper and cite their sources.
Heparin outperformed agents in rat arterial thrombosis; leaves open translation to human clinical use.
Rat carotid arteries were injured electrically (350 V, 2 mA DC for 5 min) before and after the intravenous administration of heparin (1,000 U/kg), VK 744 (25, 50, 100 mg/kg) ASA (100, 200 mg/kg) and sulfinpyrazone (50, 100, 150, 200 mg/kg). Thrombus growth was quantified by recording arterial temperature change distal to the injury. Heparin completely blocked thrombus formation in most experiments. All other agents exhibited antithrombotic activity with sulfinpyrazone being most potent. None was as effective as heparin. This model may be a useful tool for screening antithrombotic drugs.
No takes yet. Share an insight, caveat, or question.
Philp et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: